Results 51 to 60 of about 22,402 (256)
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
New England Journal of MedicineBACKGROUND Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors.
Régis Peffault de Latour +52 more
semanticscholar +1 more source
Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria
Frontiers in Immunology, 2022 Paroxysmal Nocturnal Hemoglobinuria (PNH) is a disease as simple as it is complex. PNH patients develop somatic loss-of-function mutations in phosphatidylinositol N-acetylglucosaminyltransferase subunit A gene (PIGA), required for the biosynthesis of ...
Melissa A. Colden +3 more
semanticscholar +1 more source
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
Therapeutic Advances in Hematology, 2022 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic hematologic disorder associated with inappropriate terminal complement activity on blood cells that can result in intravascular hemolysis (IVH), thromboembolic events (TEs), and organ damage ...
A. Kulasekararaj +4 more
semanticscholar +1 more source
Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria.
BloodParoxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal hematopoietic disorder. There are two components to the pathogenesis of PNH: (i) a mutant stem cell, (ii) expansion of the mutant clone. Component (i) is straightforward: there is almost
L. Luzzatto, S. Nakao
semanticscholar +1 more source
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Haematologica, 2020 Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis due to the absence of complement regulators CD55 and CD59 on affected erythrocytes.
A. Risitano +8 more
semanticscholar +1 more source
Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria.
Blood, 2022 Approximately a third of patients with paroxysmal nocturnal hemoglobinuria (PNH) remain transfusion dependent or have symptomatic anemia despite treatment with a C5 inhibitor.
G. Gerber, R. Brodsky
semanticscholar +1 more source
Effect of Dietary Phosphate Deprivation on Red Blood Cell Parameters of Periparturient Dairy Cows
Animals, 2023 Postparturient hemoglobinuria is a sporadic disease characterized by intravascular hemolysis and hemoglobinuria in early lactating dairy cows. The condition has empirically been associated with phosphorus (P) deficiency or hypophosphatemia; however, the ...
Lianne M. van den Brink +6 more
doaj +1 more source
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria
Blood, 2021 Complement has emerged as a likely driver of the immune response and end-organ damage in COVID-19. In patients with severe disease, deposition of terminal complement and micro-thrombosis have been observed in the lung, skin, kidney, and heart.
G. Gerber +6 more
semanticscholar +1 more source
Zhongguo shuxue zazhiObjective To analyze a case of hyperhemolytic syndrome(HHS) and explore the laboratory diagnostic method and clinical treatment strategy. Methods Serological tests such as blood typing, direct antiglobulin test(DAT), anti-screening and antibody ...
Zhengcai AO, Wenlei ZHU, Mingju XIAO
doaj +1 more source
Oxidative Stress and Antioxidant Activity in Buffaloes with Postparturient Hemoglobinuria [PDF]
Benha Veterinary Medical Journal, 2018 The study aims to assess the relation between oxidative stress, antioxidant activity and postparturient hemoglobinuria on70 hemoglobinuria and 30 apparently healthy buffaloes.
Hayat. Fayed +3 more
doaj +1 more source